Sangamo Therapeutics Inc (SGMO) Expected to Post FY2019 Earnings of ($1.35) Per Share

Sangamo Therapeutics Inc (NASDAQ:SGMO) – Equities research analysts at Jefferies Financial Group dropped their FY2019 earnings per share estimates for shares of Sangamo Therapeutics in a research note issued on Monday, March 4th. Jefferies Financial Group analyst M. Raycroft now forecasts that the biopharmaceutical company will post earnings of ($1.35) per share for the year, down from their previous forecast of ($0.72). Jefferies Financial Group also issued estimates for Sangamo Therapeutics’ FY2020 earnings at ($0.19) EPS, FY2021 earnings at ($1.53) EPS and FY2022 earnings at ($0.38) EPS.

Get Sangamo Therapeutics alerts:

Several other equities research analysts have also commented on SGMO. ValuEngine upgraded shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, March 1st. BidaskClub downgraded shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, November 13th. Zacks Investment Research downgraded shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 18th. Wedbush set a $11.00 target price on shares of Sangamo Therapeutics and gave the company a “hold” rating in a research report on Monday, November 19th. Finally, JPMorgan Chase & Co. downgraded shares of Sangamo Therapeutics from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $35.00 to $11.00 in a research report on Wednesday, November 14th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $16.60.

NASDAQ:SGMO opened at $9.70 on Thursday. The company has a quick ratio of 6.32, a current ratio of 6.32 and a debt-to-equity ratio of 0.07. The stock has a market capitalization of $901.48 million, a price-to-earnings ratio of -13.86 and a beta of 2.84. Sangamo Therapeutics has a 52 week low of $6.26 and a 52 week high of $26.90.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Advisors Asset Management Inc. grew its stake in Sangamo Therapeutics by 305.3% in the second quarter. Advisors Asset Management Inc. now owns 21,187 shares of the biopharmaceutical company’s stock valued at $301,000 after purchasing an additional 15,960 shares in the last quarter. Russell Investments Group Ltd. grew its stake in Sangamo Therapeutics by 194.9% in the third quarter. Russell Investments Group Ltd. now owns 105,894 shares of the biopharmaceutical company’s stock valued at $1,795,000 after purchasing an additional 69,984 shares in the last quarter. Private Advisor Group LLC purchased a new position in Sangamo Therapeutics in the third quarter valued at about $245,000. Wells Fargo & Company MN grew its stake in Sangamo Therapeutics by 12.7% in the third quarter. Wells Fargo & Company MN now owns 890,234 shares of the biopharmaceutical company’s stock valued at $15,089,000 after purchasing an additional 100,253 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. purchased a new position in Sangamo Therapeutics in the third quarter valued at about $182,000. 62.46% of the stock is owned by institutional investors.

In other news, VP Edward R. Conner sold 5,000 shares of the stock in a transaction that occurred on Monday, January 7th. The shares were sold at an average price of $12.33, for a total transaction of $61,650.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 20,000 shares of company stock valued at $224,050 over the last three months. Insiders own 1.20% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

See Also: How Does the Quiet Period Work?